de Notaristefani Carlo 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed May 20, 2019
Insider Transaction Report
Form 4
de Notaristefani Carlo
Executive VP Global Operations
Transactions
- Exercise/Conversion
Restricted Share Units
2019-05-16−1,204→ 0 total→ Ordinary Shares (1,204 underlying) - Exercise/Conversion
Ordinary Shares
2019-05-16+1,204→ 19,412.727 total - Sale
Ordinary Shares
2019-05-16$11.76/sh−629$7,397→ 18,783.727 total
Footnotes (6)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]The Ordinary Shares were received for no consideration upon the satisfaction of performance criteria underlying an award of performance share units.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F6]Restricted share units were granted on February 12, 2019 pursuant to the satisfaction of performance criteria and vested on May 16, 2019.